164 related articles for article (PubMed ID: 38637844)
21. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
Bilal H; Mahmood S; Rajashanker B; Shah R
Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
23. A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
Tonneau M; Richard C; Routy B; Campeau MP; Vu T; Filion E; Roberge D; Mathieu D; Doucet R; Beliveau-Nadeau D; Bahig H
Radiother Oncol; 2023 Aug; 185():109697. PubMed ID: 37169303
[TBL] [Abstract][Full Text] [Related]
24. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
25. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
28. A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly.
Wang P; Zhang D; Guo XG; Li XM; Du LH; Sun BJ; Fang XQ; Guo YH; Guo J; An L; Qu GP; Liu CT
Medicine (Baltimore); 2016 Dec; 95(52):e5723. PubMed ID: 28033277
[TBL] [Abstract][Full Text] [Related]
29. Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer.
Holmes OE; MacRae R; Cook G; Cross P; Nair V; Marginean H; Pantarotto JR
Clin Transl Radiat Oncol; 2017 Aug; 5():37-41. PubMed ID: 29594215
[TBL] [Abstract][Full Text] [Related]
30. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
32. Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
Palma DA; Chen H; Bahig H; Gaede S; Harrow S; Laba JM; Qu XM; Rodrigues GB; Yaremko BP; Yu E; Louie AV; Dhaliwal I; Ryerson CJ
BMC Cancer; 2019 Dec; 19(1):1206. PubMed ID: 31829203
[TBL] [Abstract][Full Text] [Related]
33. [Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy].
Kołodziejczyk M; Kępka L; Tyc-Szczepaniak D; Wierzchowski M
Pneumonol Alergol Pol; 2011; 79(5):326-36. PubMed ID: 21861256
[TBL] [Abstract][Full Text] [Related]
34. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
[TBL] [Abstract][Full Text] [Related]
35. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
[TBL] [Abstract][Full Text] [Related]
36. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Aghdam N; Lischalk JW; Marin MP; Hall C; O'Connor T; Campbell L; Suy S; Collins SP; Margolis M; Krochmal R; Anderson E; Collins BT
Front Oncol; 2021; 11():728519. PubMed ID: 34912703
[TBL] [Abstract][Full Text] [Related]
37. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
38. Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer.
Dreyer J; Bremer M; Henkenberens C
Radiat Oncol; 2018 Nov; 13(1):213. PubMed ID: 30390700
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
40. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]